Welcome,

Sign In

News

GMP laboratory for quality control and release of medicines in the Barcelona Science Park

Farmaprojects has its own GMP-certified laboratory at the Barcelona Science Park (PCB) for the import and release of medicines in the European Union (EU).
24/11/2022

Ensure the sustainability of generics production, key for European health systems

The Executive Committee of Medicines for Europe, an industry organization representing generics and biosimilars manufactures in Europe, has issued an open letter to European Union (EU) health ministers, the EU Commissioner of Health and Food Safety and other EU Commissioners to address inflation in pharmaceutical manufacturing.
24/11/2022

Farmaprojects will be present in CPHI 2022, the biggest pharma industry event

Farmaprojects will be present in the 2022 edition of CPHI, one of the most important international pharma industry events that this year will take place in Frankfurt (Germany) from November 1st to 3rd.
24/11/2022

Diabetes prevalence will increase in Europe up to 13%

According to the International Diabetes Federation (IDF) Atlas, diabetes prevalence (9.2%) and number of people with diabetes (61 million) in EUR Region will increase 13 % by 2045.
24/11/2022

The effect of patents on the increase in the cost of medicines

In recent months, the debate on patent effects on the cost of medicines and, at the end, on the very sustainability of public health systems has been taking place in Europe and the United States. Although it is true that patent system can provide incentives for innovation, on many occasions, it has led to a considerable increase in the cost of medicines which can ultimately affect patient access.
24/11/2022

Bernardo Reiner, appointed as new General Manager of Farmaprojects

Bernardo Reiner has been appointed as new general manager of Farmaprojects. Reiner has an International Degree in Economics by University of Navarra and Executive MBA by IESE Business School.
05/10/2022

Farmaprojects becomes part of the Polpharma Group

After fifteen years of uninterrupted collaboration, Farmaprojects has been integrated into Polpharma Group, one of the 20 main global players in the generic market.
05/10/2022

Farmaprojects takes part in euroPLX79, marketplace for pharma business opportunities

Farmaprojects has been present in Vienna in euroPLX79, an exchange for licenses, products, assets, distribution deals and other Pharma Business Opportunities
05/10/2022

Pages

Legal information

© 2022, Farmaprojects. All Rights Reserved.

For more information and updates regarding available dossiers and dossiers under development please contact Sales Department.
DISCLAIMER: Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s). Based on exemption under art. 5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Rivaroxaban and Ticagrelor, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.

Pages

Legal information

© 2022, Farmaprojects. All Rights Reserved.

For more information and updates regarding available dossiers and dossiers under development please contact Sales Department.
DISCLAIMER: Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s). Based on exemption under art. 5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Rivaroxaban and Ticagrelor, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.

Contact Sales Team

Let's meet our sales team